Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

Authors

Macarena I de la Fuente, University of Miami
Brian A Van Tine, Washington University School of Medicine in St. Louis
et al.

Journal

Neuro-Oncology

Publication Date

1-5-2023

Volume

25

Issue

1

First Page

146

Last Page

156

Document Type

Open Access Publication

DOI

10.1093/neuonc/noac139

Rights and Permissions

Macarena I de la Fuente, Howard Colman, Mark Rosenthal, Brian A Van Tine, Danijela Levacic, Tobias Walbert, Hui K Gan, Maria Vieito, Mohammed M Milhem, Kathryn Lipford, Sanjeev Forsyth, Sylvie M Guichard, Yelena Mikhailov, Alexander Sedkov, Julie Brevard, Patrick F Kelly, Hesham Mohamed, Varun Monga, Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial, Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 146–156, https://doi.org/10.1093/neuonc/noac139. © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

Recommended Citation

de la Fuente, Macarena I; Van Tine, Brian A; and et al., "Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial." Neuro-Oncology. 25, 1. 146 - 156. (2023).
https://digitalcommons.wustl.edu/oa_4/1002

Additional Links

Supplemental material is available for this article at publisher site.